SSGJ-705 / 3SBio - LARVOL DELTA

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov) - P2 | N=340 | Recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Lung Cancer • Oncology • Solid Tumor

SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors (clinicaltrials.gov) - P2 | N=340 | Not yet recruiting | Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Monotherapy • New P2 trial • Lung Cancer • Oncology • Solid Tumor

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors (clinicaltrials.gov) - P1; N=162; Not yet recruiting; Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor • HER-2

Guojian Pharma’s HER2/PD-1 bispecific to enter clinic in US (GBI Health) - "China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc., (HKEX: 1530), announced receipt of the US FDA's go-ahead to initiate a Phase I clinical trial for the bispecific antibody (BsAb) SSGJ-705. The targeted indication is HER2-positive advanced or metastatic solid tumors."

IND • New P1 trial • Oncology • Solid Tumor